ClinicalTrials.gg
Not yet recruitingNCT06476704PRACTISSUpdated Jun 4, 2026

Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas

A Phase 2 interventional study of Administration of L-TC and HFRT alone in Sarcoma, sponsored by Centre Paul Strauss. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Centre Paul Strauss · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Sarcoma with a site in France — 49 open to participants now, 63 under way, 8 of them phase 3. Sarcoma · France.

Planned enrollment
128th of 152
42 · median 115
Started
2026
with 5 others
Phase 2
51 of 175
9 open now
Primary completion
2028-10
later than 42 of 62 live
Registered
158th of 175
by date

Among the 175 studies in Sarcoma with a site in France, this one is the 128th largest by planned enrollment of the 152 interventional ones that give a count, is one of 6 that started in 2026, is one of 51 in phase 2, reaches primary completion later than 42 of the 62 other live ones, and was the 158th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

49 of the 175 studies in Sarcoma with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Sarcoma with a site in France, or all of them as a file.
02

Study summary

This is phase II randomized, multicenter study of treatment with L-TC and preoperative HFRT in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.

Eligible patients will be randomly assigned 2:1 to receive a preoperative HFRT alone (Arm A) or L-TC with preoperative HFRT (Arm B).

Read the detailed description

This is a non-comparative phase II trial (comparison is made regarding a reference, not 2 between 2 proportions). Considering the wide confidence interval retrieved in literature regarding pCR value with HFRT, pCR value used in the sample size calculation and taken from the literature must be included in the 95% CI of the pCR from the control group.

The PRACTISS trial aims to improve treatment outcomes for patients with extremity STS by incorporating Liposomal Transcrocetin (L-TC) with Hypofractionated Radiotherapy (HFRT). L-TC is designed to enhance tumor oxygenation, addressing hypoxia-a significant factor contributing to radioresistance. By reoxygenating tumor cells, L-TC may improve radiosensitivity, increasing the efficacy of radiotherapy and leading to higher rates of pathological complete response (pCR) before surgery. Achieving a higher pCR is associated with better long-term outcomes and reduced recurrence rates. Additionally, the use of HFRT reduces the overall treatment schedule compared to conventional radiotherapy, minimizing the treatment burden for patients and potentially improving their quality of life while maintaining treatment effectiveness.

L-TC 300 mg QD, administered as intravenous infusion over 90 minutes, at a fixed dose of 300 mg daily before each HFRT fraction, for a total of 5 days corresponding to the planned five daily HFRT fractions. The intravenous infusion should start 120 minutes before each HFRT fraction. Radiotherapy is scheduled to coincide with the plasma peak, which occurs approximately 2 hours after the start of the infusion

03

Conditions studied

  • Sarcoma

Keywords

  • hypofractionated radiotherapy
  • soft tissue sarcoma
  • hypoxia
  • liposomal transcrocetin
  • neo-adjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Localized or locally advanced soft tissue sarcoma of extremity proven by histological grade 2 and 3.
  • Pathological expert proof-reading in reference centers
  • HFRT and surgery planned (regardless the potential inclusion in this trial) as decided in a multidisciplinary tumor board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021)
  • R0 surgery is feasible, in reference centers
  • Pre-biopsy MRI available
  • Performance status of 0-2 and of at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Patient who cannot undergo MRI
  • Patients with localized or locally advanced soft tissue sarcoma of extremity proven by with histological grade 1
  • Previous radiation in the area
  • Woman who is pregnant or breastfeeding
  • Soft tissue sarcoma developed in irradiated area.
  • Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans
  • Patient with disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Hypofractionated radiotherapy + Liposomal Transcorcetin (L-TC)

    L-TC as an IV infusion over 90 minutes at a fixed dose of 300 mg daily before each HFRT fraction, for a total of 5 days corresponding to the planned five daily HFRT fractions. The intravenous infusion should begin 2 hours before each HFRT fraction. Radiotherapy is scheduled to coincide with the plasma peak, which occurs approximately 2 hours after the start of the infusion. + HFRT treatment will be administered in control group as 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.

    Drug: Administration of L-TC

  • Active comparator
    Hypofractionated radiotherapy alone

    HFRT treatment will be administered in control group as 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.

    Radiation: HFRT alone

Interventions

  • DrugAdministration of L-TC

    Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session

  • RadiationHFRT alone

    HFRT : 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.

06

What researchers measure

Primary outcomes

  1. Evaluation of the efficacy of the L-TC treatment in combination with preoperative hypofractionated radiotherapy (HFRT)

    Pathological complete response rate (pCR): defined as the presence of \< 10% residual malignant viable cells.

    Time frame: At surgery (Between 4 and 8 weeks after the end of radiotherapy)

Secondary outcomes

  1. Evaluation of the acute tolerance o f L-TC

    Toxicities and biological analysis before each injection of L-TC and before surgery, described by type and grade, using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 classification

    Time frame: Up to day 5 (every day during the treatment)

  2. Evaluation of the late tolerance o f L-TC

    Toxicities and biological analysis before each injection of L-TC and before surgery, described by type and grade, using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 classification

    Time frame: Up to day 28 after the end of treatment.

  3. Evaluation of the acute tolerance of radiotherapy

    Global tolerance (radiotherapy toxicities (oedema, radiodermatitis, fibrosis, bone fracture) and laboratory abnormalities) at each physician consultation for radiotherapy and at follow-up, using the CTCAE v.5.0 classification

    Time frame: Up to day 5 (every day during the treatment)

  4. Evaluation of the late tolerance of radiotherapy

    Global tolerance (radiotherapy toxicities (oedema, radiodermatitis, fibrosis, bone fracture) and laboratory abnormalities) at each physician consultation for radiotherapy and at follow-up, using the CTCAE v.5.0 classification

    Time frame: at 4 months after surgery, and at 12, 18, 24, 36 and 60 months

  5. Evaluation of tumour necrosis

    Proportion of patient whom tumor has pathologic necrosis on histologic examination

    Time frame: At surgery (Between 4 and 8 weeks after the end of radiotherapy)

  6. Evaluation of the radiological response

    Proportion of patients with a complete or partial radiological response (according to RECIST 1.1) evaluated on MRI

    Time frame: at screening and before surgery

  7. Proportion of patients with R0 resection

    Number of patients with R0 resection on the number of enrolled patients

    Time frame: At surgery

  8. Evaluation of the Local Progression-Free Survival (L-PFS)

    L-PFS will be defined as the length of time from the date of diagnostic by biopsy to the date of local relapse on MRI. L-PFS will be determined in median and rate

    Time frame: at 12, 24, 36 and 60 months.

  9. Evaluation of the Distant Progression-Free Survival (D-PFS)

    D-PFS will be defined as the length of time from the date of diagnostic by biopsy to the date of distant relapse on scanner. D-PFS will be determined in median and rate

    Time frame: at 12, 24, 36 and 60 months.

  10. Evaluation of the Overall Survival (OS)

    OS will be defined as the length of time from the date of diagnostic by biopsy to the date of death, whatever the cause. Patients will be censored on the last news date. OS will be determined in median and rate

    Time frame: at 12, 24, 36 and 60 months

  11. Evaluation of the Quality of Life (QoL)

    Use of the European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire (QLQ-C30)

    Time frame: at the inclusion (baseline) and every 4 months the two first years and then every 6 months the next three years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2028, 27 months later.

Of 198 non-industry phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 91. This study's planned 27 months is below that.

Counting every sponsor, half of 227 studies reached it within 66 months; a quarter within 43 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jun 26, 2024
StartEst.
Jul 1, 2026
Primary completionEst.
Oct 15, 2028
CompletionEst.
Jun 1, 2033
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06476704
Lead sponsor
Centre Paul Strauss
Collaborators
LEAF4Life, Inc.
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Jul 1, 2026 (estimated)
Primary completion
Oct 15, 2028 (estimated)
Completion
Jun 1, 2033 (estimated)
Last update
Jun 4, 2026

Study contacts

Manon VOEGELIN
Contact
promotion-rc@icans.eu
368339523 ext. +33
Isabelle CHAMBRELANT, MD
principal investigator · Institut de cancérologie Strasbourg Europe
Georges NOEL, MD, PhD
study chair · Institut de cancérologie Strasbourg Europe

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion